You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

Details for Patent: 10,695,354


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,695,354 protect, and when does it expire?

Patent 10,695,354 protects APTIOM and is included in one NDA.

This patent has seven patent family members in six countries.

Summary for Patent: 10,695,354
Title:Methods of treatment of partial onset seizures using eslicarbazepine acetate
Abstract: The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.
Inventor(s): de Almeida; Jose Luis (Arouca, PT), Soares da Silva; Patricio Manuel Vieira Ara (Oporto, PT)
Assignee: Bial-Portela & CA S.A. (Sao Mamede do Coronado, PT)
Application Number:16/449,057
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;

Drugs Protected by US Patent 10,695,354

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 AB RX Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES ⤷  Sign Up
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 AB RX Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF PARTIAL-ONSET SEIZURES ⤷  Sign Up
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 AB RX Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF PARTIAL-ONSET SEIZURES ⤷  Sign Up
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 AB RX Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES ⤷  Sign Up
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 AB RX Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES ⤷  Sign Up
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 AB RX Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF PARTIAL-ONSET SEIZURES ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,695,354

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 055939 ⤷  Sign Up
Australia 2005331690 ⤷  Sign Up
Brazil PI0520258 ⤷  Sign Up
Canada 2607427 ⤷  Sign Up
Mexico 2007013882 ⤷  Sign Up
Mexico 366496 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.